Although patients in PD-PR/CR and PD-SD groups can both benefit from combination therapy, patients in PD-PR/CR group had higher TMB, Teff density and Teff/Treg ratio in tumor, and PD-L1 or CEA expression in cancer cells than patients in PD-SD groups. The gene discussed is CEACAM5; the disease is cancer.